Nucleic Acid Therapeutics (NATx) Core

Providing comprehensive services for the design, synthesis and testing of targeted nucleic acid modulators to advance discovery science and therapeutic development.

About Us

The Nucleic Acid Therapeutics (NATx) Core is a shared scientific resource enabling the design, synthesis, and early testing of custom oligonucleotides. Through the use of specialized equipment, technical expertise and precise execution, we work with investigators around the country to support groundbreaking research in a wide range of cross-disciplined fields. 

We provide end-to-end services and expertise to advance discovery science and the development of targeted therapies, including:

  • Scientific consultations to help define sequence, chemistry, scale, purification, quality control, and downstream testing
  • Custom oligonucleotide synthesis across multiple scales and chemistries, supporting a wide range of experimental goals
  • HPLC-based purification and quality control to support product purity, consistence, and suitability for downstream applications
  • Validation and quantification to confirm product identity and sample quality
  • RT-qPCR-based screening and early functional assessment for the evaluation of oligonucleotide performance and response

New Users

New to NATx? Tell us more about your goals:

 

Complete our New User Form

Returning users

Are you ready to request your service?

 

Submit your order

Learn more

Unsure where to start? 

 

Learn more about working with NATx

Announcements

A new $3.9 million award from the NIH will help U-M researchers develop a novel antisense oligonucleotide (ASO) medicine for CLN3 Batten disease, a rare, fatal genetic disorder.

Synthesis services will be delayed October 12 to 14, while the NATx Core attends the the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society to learn about the latest nucleic acids research and technologies.

You can now apply for funding to support your NATx screening project through Michigan Drug Discovery.

Michigan Drug discovery partners with scientific cores — including the NATx Core — to advance drug discovery research through funding opportunities and scientific support. The fall funding cycle is now open, offering funding to support assay development, high-throughput screening or lead optimization. 

Proposals are due by 11:59 p.m. on October 23, 2026.

The NATx Core celebrated its grand opening at the Life Sciences Institute on Sept. 24. In our new location, we continue to be a campus-wide resource, expanding opportunities for investigators across the university and around the world to access and discover nucleic acid–based therapies and research tools.

Featured News